BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

LinkMed Release: Olerup SSP Broadens its Portfolio with HLA Sequencing Based Typing Products from Australian Company Conexio


5/4/2011 9:13:51 AM

May 04, 2011 -- LinkMed transplantation company Olerup SSP has signed an exclusive five-year global marketing, sales and distribution agreement with the Australian company Conexio for Conexio’s SBT Resolver™- HLA Sequencing Based Typing product line and sequence analysis software. Olerup SSP will now be able to broaden its product offer towards the HLA community.

Conexio’s SBT Resolver™ products are locus specific PCR based HLA sequencing based typing (SBT) reagents. The agreement includes SBT kits and a version of Assign™ sequence analysis software. The SBT product line will be a strong complement to the HLA typing technology developed by Olerup SSP® and sold through its sales channels Olerup Inc., Olerup GmbH and sub-distributors.

Olerup SSP and Conexio have also agreed to co-develop new HLA typing products.

Olerup SSP and Conexio will jointly promote the products at the 25th EFI (European Immunogenetics and Histocompatibility) conference in Prague, Czech Republic, May 4–7, 2011.

“This is a big step for us and we expect the collaboration with Conexio to broaden and strengthen our position on the global HLA typing market with a very competitive SBT solution that complements our current product portfolio. It is also a proof that we, in a very short period of time, have been able to build a global organization that can handle distribution and sales for new innovative products towards the transplantation market. The potential for SBT is at least as big as our SSP business”, says Dr. Olle Olerup, CEO Olerup SSP.

”We looked at several different options for our SBT Resolver™ product line and sequence analysis software and felt that collaboration with Olerup SSP would enable us to best provide high quality solutions to HLA typing laboratories. We are now looking forward to a long and healthy collaboration with Olerup SSP”, says Dr David Sayer, CEO and co-founder of Conexio.

Conexio

Conexio is a Western Australian company that specializes in the development of sequencing technology for HLA typing and mutation detection. Currently over 100 research and hospital laboratories throughout the world use Conexio’s sequence analysis software Assign™ and SBT reagents sold under license through other companies. The Assign™ software and SBT Resolver™ reagents facilitate high throughput DNA sequencing as an accurate method for HLA typing.

For more information please contact:

Olle Olerup, CEO Olerup SSP, phone: +46 (0)70-317 90 98 or email:olle.olerup@olerup.com.

Or visit www.olerup.com or www.linkmed.se

LinkMed AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 13:00 (CET) on May 4, 2011.

LinkMed develops life science companies in collaboration with innovators and other financiers. By contributing management and capital, LinkMed has created a portfolio of thirteen companies, four in drug development and biotechnology and nine in diagnostics and medical technology. The company’s principal shareholders are Mohammed Al Amoudi, FastPartner AB (publ), and Mannersons Fastighets AB. LinkMed is listed on the NASDAQ OMX Stockholm Exchange in the Small Cap section (ticker: LMED).



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES